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Introduction
Primary neuroendocrine tumors of the thymus (NETTs) 
have been described for the first time by Rosai and Higa 
in 1972 (1). NETTs were exceedingly rare neoplasms, 
accounting for approximately 0.4% of all carcinoid 
tumors (2) and less than 5% of all the anterior mediastinal 
neoplasms (3). An age-adjusted incidence rate of 0.18 
per 1,000,000 persons in the United States, with a male 
predominance (male-to-female ratio, 3:1), was recently 
observed (4).
Unlike neuroendocrine tumors arising from the gastro-
enteropancreatic tract or from the lung, NETTs presented 
with a very aggressive biological behavior. Furthermore, it 
has been found that these neoplasms are malignant in more 
than 80% of cases, as opposed to lung carcinoids, which 
are regarded as malignant in approximately 25% of cases, 
only (5).
According to the 2015 World Health Organization 
(WHO) tumors classification (6), NETTs still continue 
to be included in the thymic carcinoma group (7,8), and 
were classified into 4 histological entities, in 2 major 
histopathological types: well-differentiated neuroendocrine 
carcinomas (typical and atypical carcinoids) and poorly 
differentiated ones (small-cell and large-cell neuroendocrine 
carcinomas).
Since the first report, no more than 400 NETTs cases 
have been reported in the literature: the majority were case 
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reports, and only few articles reported modest series from 
single Institutions. The majority of these were too small to 
provide uniform assessment and validated prognostic factors 
for these uncommon neoplasms. Recently, two papers were 
based on large retrospective databases (4,9); therefore, 
more data were available about clinical variables influencing 
survival and recurrence development. 
Clinical features and treatment 
NETTs were predominantly located in the anterior 
mediastinal space (very rarely they presented in the middle 
or posterior mediastinum), and showed a particular 
predilection for men, typically in their fourth/fifth decades 
of life (9).
Filosso et al. (10) reported a limited percentage of 
NETTs patients (8.3%) with a history of synchronous/
metachronous second cancer, in contrast to thymomas, in 
which up to 24% of cases had a second tumor. 
From the clinical point of view, NETTs may manifest as 
follows: (I) asymptomatic, incidentally found performing a 
chest X-ray for other reasons (in approximately one third of 
cases); (II) with symptoms caused by thoracic/mediastinal 
structures displacement/compression/invasion; (III) 
associated with endocrinopathies or (IV) with symptoms 
caused by distant metastases, usually liver, brain, lung or 
bone (in approximately 20% of patients).
Thoracic and mediastinal symptoms varied according 
to the extent of the lesion, and it may range from chest 
pain, cough, dyspnea to superior vena cava syndrome (in 
approximately 20% of cases), to hoarseness, laringeal nerve 
invasion, hemidiaphragm lifting, caused by phrenic nerve 
involvement. 
About 50% of NETTs patients presented with a lymph-
nodal involvement at the time of surgical resection, but 
this condition was not found to be associated with a poor 
outcome. 
Almost 50% of NETTs were functional and were 
associated with endocrinopaties, the most common of 
which were Cushing’s syndrome (adrenocorticotropic 
hormone-ACTH-ectopic production), acromegaly (growth 
hormone releasing hormone-GH-RH-hypersecretion) 
and hypertropic osteoarthropaty (11). Multiple endocrine 
neoplasia-1 (MEN-1) syndrome (Wermer syndrome) was 
seen in 19% to 25% of NETTs; this tumor represents 
the major cause of death in MEN-1 patients (11). Finally, 
myasthenia gravis (MG), which was the most common 
paraneoplastic syndrome in thymomas, has been incidentally 
described in a man with NETT (12), whilst carcinoid 
syndrome was very rarely observed. 
NETTs radiological diagnostic workup usually included 
chest X-ray and computed tomography (CT) scan. The 
somatostatin receptors presence in the neoplastic tissue 
justified the use of 111-Indium-diethylenetriamine 
pentaacetic acid-D-phenylalanine-octreotide (Octreoscan) 
scintigraphy, both in preoperative and in follow-up settings.
18FDG PET scan very often was positive, especially in 
case of large, locally aggressive and with high-proliferation 
index tumors. Magnetic resonance imaging (MRI) was 
commonly recommended to rule out possible tumor 
invasion in adjacent mediastinal structures. 
Compared to thymic carcinomas, NETTs were more 
likely larger in size (thymic carcinoma median tumor size: 
6.2 cm; NETT median size: 7.9 cm) thymic carcinomas, on 
the other side, presented in advanced stage more frequently 
than NETTs (13,14). Approximately 50% of NETTs 
were encapsulated, but very often, gross invasion of the 
surrounding mediastinal structures was observed. Very 
frequently, NETTs presented with central foci of necrosis 
or hemorrage, especially in large lesions (Figure 1).
A preoperative histological confirmation should be 
generally achieved in case of large locally invasive tumors, 
or in case of functional lesions, as well as in asymptomatic 
but fast-growing mediastinal lesions. In particular, core 
biopsy or parasternal mediastinotomy (the so called 
Chamberlain procedure) were the preferred approaches 
to obtain a correct histological confirmation. In fact, a 
differential diagnosis with other mediastinal lesions, such 
Figure 1 Large (>15 cm) completely resected NETT. NETT, 
neuroendocrine tumor of the thymus.
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as thymomas, thymic carcinomas or lymphomas was 
always needed. 
NETT’s patients should be routinely referred and 
approached in a multidisciplinary setting, as well as in 
experienced centers (15). Indeed, in case of invasive/
advanced NETTs, an aggressive multidisciplinary treatment 
(induction chemotherapy, followed by surgery and 
postoperative chemo and/or radiotherapy) was indicated 
(16-18). Resection of the primary tumor along with the 
invaded mediastinal structures should be always performed. 
Median sternotomy was the preferred access to resect a 
NETT. In case of advanced tumors (with great vessels 
or lung invasion or pleural deposits), anterior, lateral or 
posterolateral thoracotomy, alone or in combination with 
sternotomy may be used. These accesses provided an 
excellent exposure to all the mediastinum and the pleural 
space (19,20) (Figure 2). Therefore, limited surgical 
approaches or minimally-invasive techniques had usually no 
role in NETTs surgery. 
Resectability rate ranged from 28% to 100% (mean: 
86%) in the published series. It mainly depended on 
the single center’s surgical experience (21). Incomplete 
resections mostly resulted from NETT local invasiveness, 
with tumoral residuals in great vessels, heart, trachea, aorta 
or phrenic nerves. As a matter of fact, debulking surgery 
usually had no role in aggressive neoplasms like NETTs (22).
Even in case of complete resection, prognosis was 
poor, due to the NETTs aggressive behavior along with 
a high incidence of tumor recurrences after surgery. Like 
thymomas, NETTs recurrences may classified as local 
(in the anterior mediastinum), regional (intrathoracic) 
or distant (outside the chest or in case of intrapulmonary 
nodules) .  Recurrent local  disease was sometimes 
surgically approached, if a complete resection was deemed 
feasible. Few cases have been described in the literature 
(23-25): we observed 3 relapses (2 local, 1 intrathoracic) 
in our recent 6 operated NETTs, in which surgery 
was effective (unpublished data) (Figure 3). Successful 
aggressive surgical approach (sometimes with the use of 
cardiopulmonary by-pass) and postoperative RT have 
been reported to be effective in recurrent NETTs, with 
significative improvement of survival (26-28). Currently, 
Peptide receptor radionuclide therapy (PRRT) seemed to 
be very effective for the systemic treatment of metastatic 
neuroendocrine tumors, where surgery was not feasible. 
PRRT is a form of molecular targeted therapy performed 
by using a small peptide (a somatostatin analog similar 
to octreotide) coupled with a radionuclide emitting beta 
radiation. The tumor absorbs both the drug and the 
radionuclide and the emitted beta particles will kill the 
neoplastic cells. The most effective radionuclides currently 
used are 177Lutetium and 90Yttrium.
Finally, since NETTs were the main cause of death in 
MEN-1 patients, several Authors recommend a prophylactic 
resection of the thymus at the time of parathyroidectomy, 
using the same surgical access (13,29-31). This condition 
reduced the risk of NETTs occurrence during life.
Prognostic factors
Reported intermediate-term survival in NETTs patients 
was fairly good, especially in case of complete surgical 
resection. Table 1 showed treatment, overall survival (OS) 
and cumulative incidence of recurrence (CIR) of the most 
recent (since 1990) published NETTs series. 
Patients who underwent surgery, and those who received 
a complete resection had improved OS, compared with 
those who did not. Therefore, the possibility to undergo 
surgery and the completeness of resection were the 
strongest prognostic factors (7,19,29-30). As for thymomas, 
NETTs early stage patient survived longer and less 
frequently developed recurrences, as reported in some 
clinical series (4,10,32-34). 
The study of Filosso et al. (10), based on 205 NETTs 
cases joining the International Thymic Malignancy Interest 
Group (ITMIG) and the European Society of Thoracic 
Surgeons (ESTS) retrospective thymic databases, described 
that tumor histology was not a prognostic indicator 
for either OS and CIR. Nevertheless, this data was in 
contrast with other published series, describing fewer 
Figure 2 Combined surgical approach (median sternotomy and 
anterior left thoracotomy) to resect an invasive NETT. NETT, 
neuroendocrine tumor of the thymus.
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Figure 3 (A) Radiological imaging (Thoracic CT scan) of a local NET recurrence (red arrow); (B) intraoperative view of the lesion 
(blue arrow). CT, computed tomography; NET, neuroendocrine tumor.
Table 1 Results in the recent (since 1990) NETTs published series with more than 10 patients
Author (year) # pts R0 (%) Histology Postoperative treatment Recurrences (%) 5-y survival 10-y survival
De Montpreville (1996) 14 28 14 AC NA 71 31 0
Fukai (1999) 15 87 1 TC; 9 AC; 5 SCC 5 RT; 1 CT + RT; 1 CT 67 33 7
Moran & Suster (2000) 80 NA 29 TC; 36 AC;  
15 SCC
NA 47 28 10
Tiffet (2003) 12 75 3 TC; 6 AC; 1 SCC;  
2 LCNC
3 RT; 1 CT; 1 RT + CT 83 50 NA
Cardillo (2012) 35 97 17 TC; 13 AC;  
5 LCNC
20 RT 26 84 61
Ahn (2012) 21 81 18 AC; 3 LCNC 70 RT; 9 RT + CT 33 NA NA
Filosso (2014) 205 52 49 TC; 71 AC;  
49 LCNC-SCC;  
9 carcinoids
70 RT; 31 CT 38 68 39
#, number; NETTs, neuroendocrine tumors of the thymus; R0, complete resection; TC, typical carcinoid; AC, atypical carcinoid; SCC, 
small-cell carcinoma; LCNC, large-cell neuroendocrine carcinoma; RT, radiotherapy; CT, chemotherapy; NA, not available.
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patients (4,21,34).
Furthermore, prognosis was also dependent by the 
presence of associated endocrinopaties. As reported by 
Wick and Coll (35), patients with NETTs and Cushing’s 
syndrome or MEN-1 syndrome had a 65% 5-year 
mortality, compared to 35% mortality for those without 
paraneoplastic syndromes. 
Unlike that in advanced stage thymomas, the role of 
adjuvant CT/RT in NETTs had not yet been outlined. In 
several recent published series, a preoperative treatment 
(usually CT) was advocated to obtain tumor shrinkage with 
a consequent higher probability for a complete resection 
(21,33). On the other hand, only Tiffet and Coll (32) 
showed a better outcome (no recurrence development) for 
those patients who received RT after a complete NETT 
surgical resection. On the contrary, Cardillo (21) and 
Gaur (36) reported a detrimental postoperative RT effect. 
In addiction, Filosso et al. (10) did not find any statistical 
advantage in OS for adjuvant CT/RT; furthermore, CIR 
was not statistically influenced by induction/adjuvant 
treatments. Anyway, a trend to administer induction CT 
± RT and adjuvant CT/RT according to the NETT’s 
invasiveness, resection status and possible presence of 
lymphnodal involvement was recently observed. The 
exact CT/RT role in NETTs should be studied in future 
randomized clinical trials (37). 
Due to the high risk of recurrence or distant metastases 
development, a close and life-long clinical-radiological 
follow-up was mandatory for NETTs patients. The Authors 
suggested that a Thoracic CT scan every 6 months for the 
first 3 years should be performed; in case of recurrence, 
thoracic MRI and/or Octreoscan scintigraphy may be 
indicated to assess the tumor’s resectability. 
Final remarks
In summary, NETTs were rare and biologically aggressive 
mediastinal neoplasms. They were more frequently 
observed in males and in about 50% of cases are associated 
with endocrinopaties. NETTs should be always approached 
in a multidisciplynary setting. As a matter of fact, surgery, 
even in advanced stages, was the mainstay of treatment: 
a complete resection through a median sternotomy or a 
combined approach (sternotomy + thoracotomy) should 
be always attempted. On the other hand, induction CT (or 
CT + RT) was usually administered in case of advanced 
NETT, with the aim to achieve tumor shrinkage, increasing 
therefore the probability of a R0 resection. Adjuvant 
RT/CT is offered in case of invasive tumors or when an 
incomplete resection has been performed. Unfortunately, 
due to the NETTs rarity, and the lack of randomized 
clinical trials, no definitive evidence on complementary 
treatment effectiveness were currently available in the 
literature. Finally, the long-term outcome was poor, even 
in case of a complete surgical resection, due to the NETTs 
high risk of recurrence or distant metastases development. 
In effect, prognosis was mainly dependent by tumor stage, 
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